Thu, Sep 18, 2014, 3:03 PM EDT - U.S. Markets close in 57 mins.

Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

fjl1946 28 posts  |  Last Activity: Sep 3, 2014 8:46 AM Member since: Feb 6, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    from the hub

    by fjl1946 Sep 2, 2014 9:19 PM
    fjl1946 fjl1946 Sep 3, 2014 8:46 AM Flag

    Microglial activation is one of the earliest brain pathologies in Tg
    Tau P301S and has been shown to correlate with hipocampal atrophy
    in this tauopathy model [20]. Interestingly, inhibition of microglial
    activation using an immunosuppressant prevented hipocampal
    atrophy, neuronal loss as well as tau hyperphosphorylation in Tg Tau
    P301S mice [20] suggesting a mechanistic link between microglial
    activation and the progression of tau pathologies. We therefore
    evaluated Iba1 level in brain and spinal cord homogenates of Tg Tau
    P301S mice as Iba1 expression is increased in activated microglia
    [36]. We observed that anatabine significantly suppressed Iba1
    expression in the brain and spinal cord of Tg Tau P301S suggesting
    that anatabine is opposing microglial activation in Tg Tau P301S
    mice. The reduction in microgliosis induced by anatabine in Tg P301S
    mice may be consequential to the reduction of tau phosphorylation
    and oligomerization. We have shown however, that in a mouse
    model of multiple sclerosis, anatabine can mitigate microgliosis in
    the brain and the spinal cord [23] which could suggest that anatabine
    can directly oppose microgliosis in Tg Tau P301S mice. Microgliosis
    occurs prior to any significant tau pathology in Tg Tau P301S mice

    Sentiment: Strong Buy

  • Reply to

    from the hub

    by fjl1946 Sep 2, 2014 9:19 PM
    fjl1946 fjl1946 Sep 2, 2014 9:28 PM Flag

    check it out at the hub


    And cooperation with/from other scientists:

    Sentiment: Strong Buy

  • fjl1946 by fjl1946 Sep 2, 2014 9:19 PM Flag

    And cooperation with/from other scientists:

    Sentiment: Strong Buy

  • Reply to

    Look at the Posts?

    by chenric37 Aug 25, 2014 7:11 PM
    fjl1946 fjl1946 Aug 25, 2014 9:09 PM Flag

    Especailly at this rice why hold ??

    Sentiment: Strong Buy

  • Reply to

    WHO invested $6,000,000?

    by pharma_treasure Aug 24, 2014 1:04 PM
    fjl1946 fjl1946 Aug 25, 2014 9:48 AM Flag

    you don't have to play guessing games just read!!

    Sentiment: Strong Buy

  • Reply to

    WHO invested $6,000,000?

    by pharma_treasure Aug 24, 2014 1:04 PM
    fjl1946 fjl1946 Aug 25, 2014 7:04 AM Flag

    Maybe you need to read the form!!!!

    Sentiment: Strong Buy

  • fjl1946 by fjl1946 Aug 23, 2014 9:31 AM Flag

    August 22 better look,someone must be seeing something positive!!!

    Sentiment: Strong Buy

  • Reply to

    keep this on top

    by rockcreekpharma Aug 9, 2014 7:33 AM
    fjl1946 fjl1946 Aug 14, 2014 10:27 PM Flag

    I agree

  • Reply to

    Absolutely NO income coming in

    by ociferdibble Aug 12, 2014 2:09 PM
    fjl1946 fjl1946 Aug 12, 2014 2:52 PM Flag

    Look at other biotechs and how they operate for years with little or no income what so ever!Raise capital to keep going if a hint of good news is there! Just like RCPI did this year!!

    Sentiment: Strong Buy

  • Reply to

    FDA

    by nextwave777 Aug 11, 2014 7:59 PM
    fjl1946 fjl1946 Aug 11, 2014 8:30 PM Flag

    Every one that has had some relief of somekind should write a letter explaining their health situation to the FDA ! Tell it like it is and ASK WHY are we losing something that has helped us with virtually no side effects and we are paying out of our own pockets to stay healthy!!! TELL IT LIKE IT IS!!!

    Sentiment: Strong Buy

  • STAY POSITIVE FOLKS

    Sentiment: Strong Buy

  • fjl1946 by fjl1946 Aug 11, 2014 7:56 PM Flag

    My thoughts about the August 11, 2014 news

    RCPI added 2 new directors on August 6, 2014

    My thought

    There is nothing in the August 11 news that RCPI did not know about before they announced on August 6, 2014 the appointment of two new directors. I am confident the two new directors were informed of the situation and were still excited enough in the prospects of the company to have their names identified as directors of the company.

    Mr. Edward J. McDonnell has extensive experience working with companies as they navigate their way through the FDA

    Ms. Lee Musgrove Canaan brings twenty-five years of financial and public capital markets experience and thirty-five years of scientific and technical expertise to our board.

    Why does the FDA need additional detail regarding the pre-clinical submissions of the IND?

    My thought

    Rock Creek Pharmaceuticals has contracted with Quintiles for the preparation and submission of an IND package for their compound. I assume Quintiles knows how to submit a proper IND submission. I ask has the FDA ever had an IND application for a drug that has been tested and used more than Anatabine has been tested and used? Could it be that the FDA wants more information so they can justify the skipping of phase 1.

    Why voluntarily submit for an NDIN?

    My thought

    The company voluntarily submitted for and NDIN to provide the FDA with preclinical and clinical data concerning the supplement. Is this a way for the FDA to say the company has complied with the warning letter?

    Review of how the nutritional supplement business may affect the company's drug.

    My thought

    What is this all about? This seems to be very bullish. It implies they believe they will get both and are going to ask the question what is the best strategy to precede forward with the IND and a NDIN

    If you get IND approval with some sort of expedited bases on the drug version do you want the supplement version in a pill form?

    You might want to use the supplement as a additive in all sorts of consumer products but not as a pill. A potential partner for the drug version might consider a supplement pill competition for the drug version. If there is a drug version and no pill version than Medicare and other insurances will help the consumer pay for the product.

    I end by restating

    RCPI just added 2 new directors and asking the question would the new directors be here if they did not like the future prospects

    Sentiment: Strong Buy

  • Reply to

    New Board Members Appointed

    by crooked_analyst Aug 6, 2014 1:11 PM
    fjl1946 fjl1946 Aug 6, 2014 2:50 PM Flag

    Mr. Edward J. McDonnell, MPH has a long, distinguished career in both the private, public and government sector. Most recently, Mr. McDonnell serves as President at Compliance Management Consulting, an independent consulting service, that provides expert advice, regulatory vulnerability assessments and compliance management know how to FDA regulated industries since 2000. Previously, Mr. McDonnell spent 5 years at Quintiles Consulting and Quintiles Quality Regulatory Alliance, (formerly BRI Quality Regulatory Alliance, where he was President and Chief Operating Officer), providing expert quality and regulatory services to the biomedical industry. Throughout this time Mr. McDonnell managed oversight of products, services, contracts, internal procedures, including U.S., European, and Pacific Rim requirements for GLP, GCP, GMP regulations and ISO 9000/Quality Systems Standards.

    Mr. McDonnell's government experience includes a twenty eight year career with the Federal Drug Administration (FDA). He spent the last seven years of his FDA career as Director of the New England District Office, where he provided executive direction to consumer protection and enforcement programs throughout the New England States and earned the FDA Award of merit for precedent enforcement actions. During his ten years as Director, Division of Compliance Programs at the FDA's, Center for Devices and Radiological Health, he was responsible for the development and application of Good Manufacturing Regulations (GMPs) for the manufacture of medical devices and for the implementation of new medical device legislation. . McDonnell started his FDA career as a Food and Drug Inspector in the Boston District Office specializing in the inspection of drug and device manufacturers. At the conclusion of his FDA career he was awarded the FDA Distinguished Career Service Award

    Mr. McDonnell earned a M.P.H., in Health Business Administration from the University of Michigan, School of Public Health, Ann Arbor, MI and a B.A., in Biology from Boston University, College of Liberal Arts, Boston, MA. Mr. McDonnell resides in both Ormond Beach, FL. and Lowell, MA

    Sentiment: Strong Buy

  • Reply to

    New Board Members Appointed

    by crooked_analyst Aug 6, 2014 1:11 PM
    fjl1946 fjl1946 Aug 6, 2014 1:55 PM Flag

    Yahoo just won't let me add the rest of this announcement!

    Sentiment: Strong Buy

  • Reply to

    New Board Members Appointed

    by crooked_analyst Aug 6, 2014 1:11 PM
    fjl1946 fjl1946 Aug 6, 2014 1:24 PM Flag

    Both Ms. Canaan and Mr. McDonnell have substantial expertise, experience and knowledge relevant to the Company's mission and anticipated needs. Effective immediately, this brings the number of independent board members to five persons, for a total board composition of seven members, including the Company's CEO and President,

    Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, said, "Lee and Ed are uniquely accomplished and highly qualified individuals, who bring substantial skill sets and professional acumen from both a public and private company perspective. With Lee's extensive experience with corporate finance and Ed's deep experience on FDA and regulatory matters, they both will complement our current board and management. We are very proud and privileged to have them join us."

    Ms. Lee Musgrove Canaan brings twenty-five years of financial and public capital markets experience and thirty-five years of scientific and technical expertise to our board. She has working knowledge of both debt and equity markets as an institutional investor and a corporate finance professional and has served on the board of several publicly-traded companies. Currently Ms. Canaan is the portfolio manager of a private money management firm she founded in 2003. Prior to that, she was a fixed income analyst for the high yield debt team at AIM Management (part of the Invesco Family of funds) after making the transition from corporate finance professional in the treasury operations of ARCO, a Fortune 100 energy company. Ms. Canaan started her career as a geophysicist at AMOCO. She also has private market investment experience and was recognized by the U.S. Department of Energy as a financial and technical expert for the purposes of evaluating government investments in the renewable energy space.

    Ms. Canaan has a B.S. in Geological Sciences from the University of Southern California, a Masters in Geophysics from the University of Texas at Austin, and an M.B.

    Sentiment: Strong Buy

  • Reply to

    HMMMMMMM!!!!

    by fjl1946 Aug 4, 2014 9:15 AM
    fjl1946 fjl1946 Aug 4, 2014 10:52 AM Flag

    Just the mention of tobaco makes you wonder!!

    Sentiment: Strong Buy

  • Reply to

    HMMMMMMM!!!!

    by fjl1946 Aug 4, 2014 9:15 AM
    fjl1946 fjl1946 Aug 4, 2014 9:17 AM Flag

    Thanks to the hub from this morning!!

    Sentiment: Strong Buy

  • fjl1946 by fjl1946 Aug 4, 2014 9:15 AM Flag

    Maggie Fox) A cocktail of antibodies cooked up in tobacco plants may provide an emergency treatment for Ebola virus, one of the deadliest viruses known, researchers reported Wednesday.

    The treatment provides 100 percent protection to monkeys when given right after exposure. But it also helps even after symptoms develop, the researchers report in the journal Science Translational Medicine.

    Ebola first appeared in 1976 and causes an especially frightening and deadly form of hemorrhagic fever. Patients die of shock but may bleed internally and externally. Depending on the strain, it kills between 25 and 90 percent of patients.

    There is no existing treatment and no vaccine. “It is horrifying,” says Gene Olinger of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), who worked on the study.

    Various strains of the virus pop up unpredictably across Africa, perhaps as people venture into forests to hunt wild animals, especially monkeys and apes, known as bushmeat. The virus infects apes and monkeys and it infects people who are exposed to bodily fluids, such as blood.

    Scientists are working on a variety of approaches to treat the virus and also to make a vaccine. This latest possible treatment comes from the vaccine work.

    “We were developing a vaccine and the vaccine was tested in mice and the mice were used to make the monoclonal antibodies to understand how they protected from disease,” Olinger said in a telephone interview.

    Antibodies are immune system proteins that recognize and attack invaders such as bacteria and viruses. Monoclonal antibodies are engineered to recognize a specific pathogen – in this case, a strain of Ebola.

    The team chose three of the antibodies and made them into a cocktail called MB-003. They’ve been testing it in monkeys, which can be infected with Ebola in much the same way as humans can.

    In this latest test, 43 percent of the monkeys recovered and survived when treated as long as five days after they were infect

    Sentiment: Strong Buy

  • Reply to

    THANKS TO IHUB POSTER

    by fjl1946 Jul 31, 2014 7:09 PM
    fjl1946 fjl1946 Jul 31, 2014 7:40 PM Flag

    A large section of this didn't print !??? Check it put at the HUB

    Sentiment: Strong Buy

  • Inflammation
    Chronic inflammation feeds a smorgasbord of chronic diseases. If you don't have a chronic disease yourself, you know someone who does. An estimated 80 percent of visits to doctor's offices are for issues

    CHRONIC DISEASE


    • Persistent or recurring disease, usually affecting a person for three months or longer

    • Generally triggered by diet and environmental contaminants

    • Standard medicine believes such diseases can be managed but rarely cured

    • Includes allergies, Alzheimer's, arthritis, asthma, cancer, COPD, Crohn's, chronic fatigue, cystic fibrosis, diabetes, emphysema, fibromyalgia, Gulf War Syndrome, heart disease and stroke, high blood pressure, Lyme, lupus, multiple sclerosis, obesity, osteoporosis, depression, anxiety, PTSD, and more

    relating to chronic disease. The CDC tells us 7 of every 10 Americans die of a chronic disease.

    Chronic inflammation gradually destroys an otherwise beautiful machine.

    If you hit your thumb with a hammer, the resulting swelling and inflammation is obvious, painful, and short lived. Your immune system sends white blood cells and other hormone-like substances to help start the healing process. Inflammation here serves a healthy purpose.

    Inflammation is the life-saving component of your immune system that helps fend off bacteria, viruses, fungi, and other microbial invaders. Without inflammation we would be sitting ducks in a very hostile world, with no way to repair the damage constantly inflicted on us.

    The Persistent Stimulus
    Inflammation goes chronic when there is a persistent stimulus. The stimulus might come from an army of free radicals launched every day when we eat foods made with processed vegetable oils – French fries, fried food, non-fat dried milk, powdered coffee creamer, most salad dressings, crackers, cookies, chips, and a plethora of other processed and convenience foods. The stimulus might be an allergy to wheat (gluten) which inflames the gut. Or a low-grade, lingering infection.

    Sentiment: Buy

STSI
0.5801-0.0519(-8.21%)Jun 3 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.